In this study, we report a rationally designed therapy to conquer BEZ235 resistance that may benefit patients with aberrant PI3K/mTOR pathway-associated nasopharyngeal carcinoma. The gene discussed is PIK3CA; the disease is nasopharyngeal carcinoma.